DUCREUX Sylvie
- Position: Assistant Professor
- Phone : + 33 (0)4.78.77.70.47
- Mail : sylvie.ducreux@univ-lyon1.fr
Team member :
Plateform member :
Find this member on networks :
Short bio
During her PhD under the supervision of Dr. Susan Treves at the University of Basel, Switzerland (2002-2006), she studied the functional effects of mutations in the ryanodine receptor type 1 (RyR1) in association with several skeletal muscle disorders (malignant hyperthermia, central cortex disease, multi-minicore disease).
As a postdoctoral researcher at the University of Fribourg in Switzerland in the group of Prof. Beat Schwaller (2006-2010), she focused on the role of parvalbumin, a Ca2+ binding protein, in skeletal muscle physiology.
During her second postdoctoral fellowship at the University Claude Bernard Lyon 1 (UCBL1) in the Center of Genetics and Molecular and Cellular Physiology (2010-2012), she contributed to establish the role of the non-selective Ca2+ channel Transient Receptor Potential Vanilloid 1 (TRPV1 ) in skeletal muscle.
Since 2012, she is a lecturer in Physiology at UCBL1 and member of the CaRMeN laboratory.
Since 2013, she is also co-leader of the CarMeN microscopy technical platform.
Today, she focuses her research work on the role of different ion channels and reticulum-mitochondria interactions in myocardial infarction and in the development of secondary cardiac events.
Skills
- Physiology & Cell Biology
- Calcium Imaging & Confocal Microscopy
- Ion channels & Ca2+ homeostasis
Funding
- 2002-2006 : PhD scholarship from the Swiss National Science Foundation.
- 2008 : PENS (Programme for European Neuroscience Schools) scholarship for the summer school “Imaging Brain Function: From Synapses to Networks” (Switzerland).
- 2009 : Travel grant from the Swiss Society for Cellular, Molecular and Genetic Biology for the 16th Congress “Ca2+ Binding Proteins and Ca2+ Function in Health and Diseases” (Chile).
- 2010: Research grant from the Swiss National Science Foundation: “Knock-out mice for the calcium-binding proteins parvalbumin, calbindin D-28k and calretinin. Models for muscle and brain diseases” = associate.
- 2014-2017: Servier Laboratories research grant: “Pharmacological modulation of ER calcium leak in cardiomyocytes undergoing hypoxia-reoxygenation” = co-principal investigator.
- 2020 & 2021 : Project Pedagogical Platforms of the Auvergne Rhône Alpes Region / UCBL1, project leader = Zeiss Digital classroom
- 2022-2025: RYP (Rise Your Project) internal funding, project leader “Role of reticulum-mitochondria interactions in B lymphocytes of patients with ischemic heart disease”.
5 major publications:
- Aude Lafoux, Sabine Lotteau, Corinne Huchet and Sylvie Ducreux. The contractile phenotype of skeletal muscle in TRPV1 knockout mice is gender-specific and exercise-dependent. Life. 2020.
- Al-Mawla R*, Ducrozet M*, Tessier N*, Païta L, Pillot B, Gouriou Y, Villedieu C, Harhous Z, Paccalet A, Crola Da Silva C, Ovize M, Bidaux G, Ducreux S‡ and Van Coppenolle F‡. Acute induction of translocon-mediated Ca2+ leak from sarcoplasmic reticulum protects cardiomyocytes against ischemia/reperfusion injury. Cells. 2020.
- Vanden Abeele F*, Lotteau S*, Ducreux S, Dubois C, Monnier N, Hanna A, Gkika D, Romestaing C, Noyer L, Flourakis M, Tessier N, Al-Mawla R, Chouabe C, Lefai E, Lunardi J, Hamilton S, Fauré J, Van Coppenolle F, Prevarskaya. TRPV1 variants impair intracellular Ca2+ signaling and may confer susceptibility to malignant hyperthermia. N. Genet Med. 2018.
- Ducreux S, Zorzato F, Ferreiro A, Jungbluth H, Muntoni F, Monnier N, Muller CR, Treves S. Functional properties of ryanodine receptors carrying 3 amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalised lymphocytes. Biochem J. 2006.
- Ducreux S, Zorzato F, Muller C, Sewry C, Muntoni F, Quinlivan R, Restagno G, Girard T, Treves S. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem. 2004.